LON:HIK - Hikma Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 1,402 -28.00 (-1.96 %)
(As of 06/25/2018 05:43 AM ET)
Previous CloseGBX 1,430
Today's RangeGBX 1,401.50 - GBX 1,446.50
52-Week RangeGBX 814.20 - GBX 2,346
Volume13,598 shs
Average Volume822,138 shs
Market Capitalization£2.67 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hikma Pharmaceuticals logoHikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:HIK
CUSIPN/A
Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.82%
Return on Equity5.69%
Return on Assets3.19%

Miscellaneous

EmployeesN/A
Outstanding Shares240,660,000

The Truth About Cryptocurrencies

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Wednesday, March 14th. Stockholders of record on Thursday, April 5th will be given a dividend of GBX 0.23 per share on Thursday, May 24th. This represents a dividend yield of 1.47%. The ex-dividend date is Thursday, April 5th. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.22. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

9 brokers have issued 1-year target prices for Hikma Pharmaceuticals' shares. Their predictions range from GBX 850 to GBX 1,560. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 1,161.33 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Press coverage about HIK stock has been trending somewhat positive on Monday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the company an impact score of 47.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,402.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £2.67 billion.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (HIK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  475 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  766
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.